Todd Tushla
Vice President of Investor Relations
Replay available
Neurocrine Biosciences, Inc. (NBIX) Q3 2025 Earnings Call
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q3 2025 earnings conference call, held 2025-10-28. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Kyle Gaino
Chief Executive Officer
Matt Abernathy
Chief Financial Officer
Eric Benevich
Chief Commercial Officer
Sanjay Kaswani
Chief Medical Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Neurocrine Biosciences, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.259 Good day, everyone, and welcome to today's Neurocrine Biosciences third quarter 2025 00:00:05.259 -- 00:00:07.442 results call. 00:00:07.442 -- 00:00:10.947 At this time, all participants are in a listen-only mode. 00:00:10.947 -- 00:00:14.853 Later, you will have the opportunity to ask questions during the question and answer 00:00:14.853 -- 00:00:16.835 session. 00:00:16.835 -- 00:00:22.984 You may register to ask a question at any time by pressing star 1 on your telephone keypad. 00:00:22.984 -- 00:00:25.929 Please note this call is being recorded. 00:00:25.929 -- 00:00:29.140 I will be standing by if you should need any assistance. 00:00:29.140 -- 00:00:34.385 It is now my pleasure to turn the conference over to Vice President of Investor Relations, 00:00:34.385 -- 00:00:36.685 Todd Tushla. 00:00:40.010 -- 00:00:44.094 Hi, everybody, and a very pleasant good afternoon to you, wherever you may be. 00:00:44.094 -- 00:00:48.538 Welcome to Neurocurrent Biosciences' third quarter 2025 earnings call. 00:00:48.538 -- 00:00:53.142 I'm joined today by Kyle Gaino, Chief Executive Officer, Matt Abernathy, Chief Financial 00:00:53.142 -- 00:00:59.009 Officer, Eric Benevich, Chief Commercial Officer, and Sanjay Kaswani, Chief Medical Officer. 00:00:59.009 -- 00:01:01.874 During our call, we will be making forward-looking statements. 00:01:01.874 -- 00:01:05.961 These statements are subject to certain risks and uncertainties, and our actual results 00:01:05.961 -- 00:01:10.028 may differ materially. I encourage you to review the risk factors discussed in our latest 00:01:10.028 -- 00:01:15.176 SEC filings. After prepared remarks and as is our standard practice, we will 00:01:15.176 -- 00:01:20.582 try to address all your questions. With that...